Harrow (NASDAQ:HROW) Announces Earnings Results

Harrow (NASDAQ:HROW - Get Free Report) posted its earnings results on Thursday. The company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.14, Zacks reports. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $66.83 million for the quarter, compared to the consensus estimate of $66.01 million.

Harrow Stock Up 1.5 %

HROW stock traded up $0.39 on Monday, hitting $26.60. 796,179 shares of the company's stock were exchanged, compared to its average volume of 498,759. The firm has a 50 day moving average price of $28.76 and a two-hundred day moving average price of $37.86. Harrow has a 12-month low of $9.86 and a 12-month high of $59.23. The stock has a market cap of $947.36 million, a P/E ratio of -28.30 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $57.00 price objective on shares of Harrow in a report on Monday. B. Riley dropped their target price on Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a research report on Wednesday, December 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.